Low Carbohydrate/High Protein Diet to Improve Metabolic Health
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03207841 |
|
Recruitment Status :
Completed
First Posted : July 5, 2017
Last Update Posted : March 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Spinal Cord Metabolic Syndrome Diabetes | Other: LC/HP | Not Applicable |
Individuals with spinal cord injury (SCI) are living to ages when metabolic disorders are highly prevalent. Due to the loss of mobility and severe skeletal muscle atrophy in individuals with SCI, obesity, impaired glucose tolerance, and peripheral insulin resistance develop after injury . The combination of impaired glucose tolerance and insulin resistance can disrupt lipid metabolism and increase the risk of cardiovascular disease and diabetes, and contribute to an accelerated aging process in the SCI population. Because of these trends, the overall burden of health complications and their economic impact has increased for individuals with SCI, often leading to a progressive decrease in their long-term quality of life. Feasible interventions to improve metabolic function (i.e. the way the body processes proteins, carbohydrates, and fats in foods) in those with chronic SCI are in great demand. Given that metabolic disorders severely compromise health outcomes and important domains of quality of life, including participation in daily life and community living and employment outcomes, targeted strategies to combat these morbidities are of paramount importance. Compared to pharmacologic therapies, dietary modification is a more cost-effective treatment option for reducing the risk of metabolic dysfunction that, surprisingly, has not been rigorously investigated in people with SCI. Much like the general U.S. population, individuals with SCI consume far more fat and carbohydrate than recommended levels. High fat, high carbohydrate diets (western diet) have been associated with a higher prevalence of obesity and metabolic disease as well as negative adaptations in the diversity of gut bacteria (increased levels of harmful bacteria and reduced levels of beneficial bacteria) that usually precedes the development of diabetes or insulin resistance. Therefore, macronutrient (carbohydrate, protein, and fat) modification may be able to prevent or correct the impaired metabolic state in persons with SCI. Diets composed of relatively high protein and low carbohydrate have been shown to improve body composition (i.e., reduce body fat while maintaining lean tissue) and metabolic profiles (i.e., increase in insulin sensitivity and glucose tolerance) in diabetic, able bodied individuals who are obese or overweight. This improvement is thought to be due to protein's: (i) effect on the sensation of feeling full after eating food despite similar or lower energy intake; (ii) contribution to storage of fat-free mass; and (iii) insulin sensitizing effect.
The investigators' pilot work supports this hypothesis in that we showed that 8 weeks of a low carbohydrate/high-protein (LC-HP) diet significantly improved whole body insulin sensitivity (WBIS) and glucose tolerance and decreased the amount of intra-abdominal fat in six men with SCI and with either untreated type 2 diabetes or impaired glucose tolerance (pre-diabetes). In addition to significant improvements in metabolic health, our pilot work also successfully demonstrated the safety and feasibility of our approach. The lack of adverse effects and the improvement in glucose control and insulin sensitivity in our study participants with SCI prompted us to propose the current study involving both men and women in order to determine the effects of the dietary protocol to treat type 2 diabetes or impaired glucose tolerance in persons with chronic SCI. Thus, the investigators propose an investigation to determine if 8 weeks of an LC/HP dietary intervention induces the physiological adaptations necessary to improve metabolic function and body composition and alter the diversity of gut bacteria in a large cohort of individuals with SCI. The ultimate outcome of this project will be an effective diet program which can be easily and economically implemented at home as a non-pharmacological means of achieving blood glucose control for people with SCI and impaired glucose tolerance or untreated type 2 diabetes.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | Utilizing a Low-Carbohydrate/High-Protein Diet to Improve Metabolic Health in Individuals With Spinal Cord Injury |
| Actual Study Start Date : | November 1, 2017 |
| Actual Primary Completion Date : | August 1, 2022 |
| Actual Study Completion Date : | August 29, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: LC/HP group
Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
|
Other: LC/HP
Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. |
|
No Intervention: Control
Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
|
- Change in glucose tolerance [ Time Frame: Week1 and Week 8 ]
- Change in insulin sensitivity [ Time Frame: Week 1 and Week 8 ]
- Change in body mass index [ Time Frame: Week 1 and Week 8 ]
- Change in gut bacterial composition [ Time Frame: Week 1 and Week 8 ]
- Change in HDL, LDL, total cholesterol and triglycerides [ Time Frame: Week 1 and Week 8 ]
- Change in Spinal Cord Injury-Quality of Life (SCI-QOL) Score [ Time Frame: Week 1 and Week 8 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Between the ages of 18 and 65 years
- diagnosis of traumatic SCI at the cervical, thoracic, or lumbar level (C5-L2) classified as American Spinal Cord Injury Association Classification (AIS) A, B, C, or D
- Impaired glucose tolerance or untreated type 2 diabetes
- at least 3 years post-injury.
Exclusion Criteria:
- Pregnant women.
- Neurological (other than SCI), vascular and/or cardiac problems that may limit function and interfere with testing procedures
- Patients with evidence of renal insufficiency and liver disease by history, physical examination, and laboratory tests
- Patients with underlying pulmonary diseases
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03207841
| United States, Alabama | |
| UAB | |
| Birmingham, Alabama, United States, 35294 | |
| Responsible Party: | Ceren Yarar-Fisher, Principal Investigator, Ohio State University |
| ClinicalTrials.gov Identifier: | NCT03207841 |
| Other Study ID Numbers: |
HHS-2016-ACL-NIDILRR-SI-0158 |
| First Posted: | July 5, 2017 Key Record Dates |
| Last Update Posted: | March 27, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
SCI High Protein Low Carbohydrate Metabolic Health Microbiome |
|
Metabolic Syndrome Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |